A Phase 1 Study of Gemcitabine, Dasatinib and Erlotinib in Patients With Advanced Pancreatic Carcinoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT01660971

Title field or adapter rule

{'original_value': 'A Phase 1 Study of Gemcitabine, Dasatinib and Erlotinib in Patients With Advanced Pancreatic Carcinoma', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:26.364722+00:00

Published At

2026-09-09T00:00:00+00:00

Record Updated At

2026-09-09

Source Retrieved At

2026-10-31T22:17:56.788771+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Metastatic Pancreatic Adenocarcinoma", "Recurrent Pancreatic Carcinoma", "Stage III Pancreatic Cancer AJCC v6 and v7", "Stage IV Pancreatic Cancer AJCC v6 and v7"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-09-09", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT01660971"

protocolSection.identificationModule.officialTitle

"A Phase 1 Study of Gemcitabine, Dasatinib and Erlotinib in Patients With Advanced Pancreatic Carcinoma"

protocolSection.statusModule.overallStatus

"ACTIVE_NOT_RECRUITING"

protocolSection.designModule.phases

["PHASE1"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Metastatic Pancreatic Adenocarcinoma (protocolSection.conditionsModule.conditions)
• Recurrent Pancreatic Carcinoma (protocolSection.conditionsModule.conditions)
• Stage III Pancreatic Cancer AJCC v6 and v7 (protocolSection.conditionsModule.conditions)
• Stage IV Pancreatic Cancer AJCC v6 and v7 (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['Treatment (gemcitabine, dasatinib, erlotinib)'], 'description': 'Given PO', 'name': 'Dasatinib', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Treatment (gemcitabine, dasatinib, erlotinib)'], 'description': 'Given PO', 'name': 'Erlotinib Hydrochloride', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Treatment (gemcitabine, dasatinib, erlotinib)'], 'description': 'Given IV', 'name': 'Gemcitabine Hydrochloride', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• Dasatinib (protocolSection.armsInterventionsModule.interventions[].name)
• Erlotinib Hydrochloride (protocolSection.armsInterventionsModule.interventions[].name)
• Gemcitabine Hydrochloride (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.